Drug
Lazucirnon clinical trials
Also written AKST4290 and BI 144807.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2018 | 2 |
| 2020 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses lazucirnon is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)TerminatedPhase 2Alkahest, Inc.NCT05038020Written as AKST4290
- A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous PemphigoidTerminatedPhase 2Alkahest, Inc.NCT04499235Written as AKST4290
- A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMDCompletedPhase 2Alkahest, Inc.NCT04331730Written as AKST4290
- Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic TreatmentCompletedPhase 2Alkahest, Inc.NCT04369430Written as AKST4290
- Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular DegenerationCompletedPhase 2Alkahest, Inc.NCT03558074Written as ALK4290
- Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular DegenerationCompletedPhase 2Alkahest, Inc.NCT03558061Written as ALK4290
- A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular DegenerationCompletedPhase 2Boehringer IngelheimNCT02121522Written as BI 144807
- Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT01480648Written as BI 144807
- Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic PatientsCompletedPhase 1Boehringer IngelheimNCT01651598Written as BI 144807
- Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed ConditionsCompletedPhase 1Boehringer IngelheimNCT01897597Written as BI 144807 high dose
Given in every arm · 1 — lazucirnon is usual care beside what is tested
Codes
What other systems call lazucirnon · ClinicalTrials.gg INT017741
- UNII (FDA) R0T9LLR4TNLAZUCIRNONOne source FDA
- NCI Thesaurus C175807LazucirnonOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R0T9LLR4TN | LAZUCIRNON | One source FDA |
| NCI Thesaurus | C175807 | Lazucirnon | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.